ClinicalTrials.gg
RecruitingNCT06691867I-STRONG SCDUpdated Nov 20, 2026

Integrative Training Program for Pediatric Sickle Cell Pain

An interventional study of I-STRONG and Enhanced Usual Care (EUC) in Sickle Cell Disease, sponsored by Emory University. Recruiting at 4 sites in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Emory University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Anemia, Sickle Cell by Emory University — 4 open to participants now, 6 under way, none of them phase 3. Anemia, Sickle Cell · Emory University.

Planned enrollment
3rd of 25
155 · median 24
Started
2025
with 1 other
No phase
12 of 29
3 open now
Registered
26th of 29
by date

Among the 29 studies in Anemia, Sickle Cell by Emory University, this one is the 3rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 with no phase, and was the 26th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 29 studies in Anemia, Sickle Cell by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Anemia, Sickle Cell by Emory University, or all of them as a file.
02

Study summary

This research aims to answer the question: does a group training program specifically for teens with chronic sickle cell disease (SCD) pain that teaches skills to strengthen the mind and body help improve everyday functioning and reduce pain symptoms?

The program will be tailored to address challenges related to frequent or chronic sickle cell pain and may improve participants' physical and emotional health.

The program, called I-STRONG for SCD (Integrative Strong Body and Mind Training for Sickle Cell Disease), may help improve everyday functioning and pain symptoms in teens with chronic pain related to SCD. The research team aims to determine how participants (teens and parents) respond to this program.

Read the detailed description

I-STRONG for SCD integrates evidence-based mind-body, cognitive-behavioral, and neuromuscular movement training. It will be tested using an individually randomized group treatment (IRGT) design, comparing early start to the enhanced usual care. The primary objective is to determine whether I-STRONG for SCD combined with standard care is more effective than standard care alone in improving pain intensity from baseline to the 3-month follow-up in adolescents with SCD.

Adolescent participants with sickle cell disease and their caregivers will be recruited for this study. Participants of all genders, races, and ethnicities are eligible, with a majority expected to be Black or African American females, consistent with previous studies of individuals with SCD and chronic pain. The study will last approximately 36 months, with participant involvement lasting 9 months.

I-STRONG for SCD has been adapted from the Fibromyalgia Integrative Training for Teens (FIT Teens) program based on feedback from patients and caregivers, focusing on chronic SCD pain. In addition to usual care, participants will receive the I-STRONG intervention, which consists of 16 group-based telehealth sessions (90 minutes each), held twice weekly for 8 weeks. All patients can participate in I-STRONG, with randomization determining whether they begin with Early Start (after completing the baseline assessment) or Enhanced Usual Care (approximately 8 months after the baseline assessment).

Support from and inclusion in the National Institutes of Health (NIH) Helping to End Addiction Long-term Initiative (HEAL), or NIH HEAL Initiative, is provided for this study. For more information about the initiative visit the HEAL Initiative (https://heal.nih.gov/).

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle Cell Pain
  • Lifestyle considerations
  • Pediatrics
  • Behavioral intervention
  • Mind-body intervention
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form for adolescents 18 years old and caregivers' participation
  • For children \<18, informed assent and parental informed consent to participate in the study
  • Willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Males and females; Ages 12-18 years for adolescents; no age limitations for caregivers
  • Documented diagnosis of sickle cell disease (any genotype) for adolescents
  • Adolescent scores at least 3 on the Pediatric Pain Screening Tool
  • Adolescent reports typical pain intensity in the past week at least 4 on a 0-10 cm Visual Analog Scale
  • Adolescent on stable disease-modifying treatments, if applicable (e.g., hydroxyurea, glutamine, voxelotor, crizanlizumab) as defined by not newly initiated or significantly increased dosages (mg/kg) in the past 3 months
  • Speak and read English

Exclusion criteria

Exclusion Criteria:

  • An adolescent has comorbid medical conditions typically associated with pain but unrelated to SCD (e.g., rheumatologic disorders or inflammatory bowel disease)
  • Adolescent has undergone genetic or hematopoietic stem cell therapy
  • Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation
  • Adolescents receiving active treatment (e.g., weekly appointments with a provider) for nonpharmacological therapies (e.g., structured behavioral pain management, physical therapy, or acupuncture program) that overlap with the active phase of the study intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    I-STRONG - Early Start

    Youth and caregivers will receive the I-STRONG for SCD intervention in addition to standard care.

    Behavioral: I-STRONG

  • Other
    Enhanced Usual Care (EUC)

    Participants randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months. After completing the 6-month follow-up assessment, participants will have the opportunity to start the I-STRONG SCD intervention.

    Other: Enhanced Usual Care (EUC)

Interventions

  • BehavioralI-STRONG

    I-STRONG is an evidence-based protocol from the FIT Teens program. This intervention combines mind-body and cognitive-behavioral approaches with neuromuscular movement training informed by pediatric sports medicine and injury prevention research. It aims to teach mind-body skills applicable during movement training to enhance psychological coping and reduce fear of pain and activity avoidance. I-STRONG consists of 16 group-based telehealth sessions held twice weekly over 8 weeks. Each group can accommodate up to 6 patients with SCD. Adolescents are expected to attend all sessions, while parents will attend 6 of the 16. Parents will receive education about I-STRONG, guidance on supporting their teen's behavior change, and opportunities for networking with other parents of youth with SCD. Sessions will include brief daily homework (e.g., using phone apps to practice skills) to facilitate proficiency. Participants will self-report their practice of assigned skills.

    Also known as: Intervention Group

  • OtherEnhanced Usual Care (EUC)

    The EUC arm is designed to account for potential effects on time and standard medical care outcomes. Patients randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months (i.e., time from enrollment through 6-month post-treatment assessment) before starting the intervention program to coincide with the study duration of the ES arm. After completing the 6-month follow-up assessment, patients will have the opportunity to start the I-STRONG for SCD intervention.

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Brief Pain Inventory (BPI) Pain severity

    Pain intensity is rated with the pain severity item of the Brief Pain Inventory (BPI). The single item is scored on a scale from 0 to 10 where no pain = 0 and severe pain = 10. This outcome applies to teens only.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

Secondary outcomes

  1. Change in Brief Pain Inventory (BPI) Pain Interference Score

    Functional interference due to pain rated with the impact of pain on daily functions item of the Brief Pain Inventory (BPI). The single item is scored on a scale from 0 to 10 where no pain = 0 and severe pain = 10. This outcome applies to teens only.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  2. Patient Health Questionnaire (PHQ-8) Score

    Depressive symptoms in past two weeks among teen study participants and parents is assessed with the Patient Health Questionnaire (PHQ-8). The PHQ-8 has 8 items that are responded to on a 4-point scale where " not at all" = 0 and "nearly every day" = 3. Total scores range from 0 to 24 where higher scores indicate increased symptoms of depression. The outcome applies to teens and parents.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  3. General Anxiety Disorder (GAD-2)

    General worry in the past two weeks among teen study participants and parents will be assessed using the GAD-2 instrument. The GAD-2 has 2 items that are responded to on a 4-point scale where " not at all" = 0 and "nearly every day" = 3. Total scores range from 0 to 6 where higher scores indicate increased experiences of worry. The outcome applies to teens and parents.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  4. Pain Catastrophizing Scale

    Exaggerated worried thoughts of pain will be assessed among teen study participants and parents. The Pain Catastrophizing Scale, Child and Parent Report, is a 13-item well-validated self-report and parent-report measure of worried thoughts about pain. Items are answered on a 5-point scale where 0 = not true at all and 4 = very true. Total scores range from 0 to 52 and higher scores indicate increased catastrophic thinking. The outcome applies to teens and parents.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  5. Pediatric Quality of Life Inventory (PedsQL) Score

    Health-related quality of life and impact on child and family in the past month is assessed among teen study participants and parents with the Pediatric Quality of Life Inventory (PedsQL). The 23-item PedsQL was developed as part of the NIH Roadmap Initiative to create universal measures for patient-reported outcomes and contains questions in the domains of social peer, depression, anxiety, mobility, and function. Responses are given on a 5-point scale where 0 = never and 4 = almost always. Items are reverse scored and linearly transformed to a scale of 0 to 100, where higher total mean scores indicate a better quality of life. The outcome applies to teens only.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  6. Adolescent Sleep-Wake Scale (ASWS) Score Short Form

    The Adolescent Sleep Wake Scale (ASWS) Short Form is a 14-item patient report describing the occurrence and frequency of various behavioral sleep characteristics over the past month. Responses are given on a 6-point Likert scale where 1 = always and 6 = never. Total scores range from 14 to 84 and higher scores indicate better sleep quality. This outcome applies to teens only.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  7. National Institute on Drug Abuse (NIDA)-Modified ASSIST (NM ASSIST) Tool Level 2 score

    Substance use among teen study participants during the past 3 months is assessed with the NIDA-Modified Assist Tool Level 2 for children aged 11-17. The instrument asks respondents how often they have used 15 different substances. Responses are given on a 4-point scale where "not at all" = 0 and "nearly every day" = 4. The tool is scored as the number of items with a score greater than 0 and multiple items with scores above 0 indicate increased substance use. This outcome applies to teens only.

    Time frame: Baseline, 3 months post-intervention

  8. Opioid Use

    Daily use of opioid pain medication will be determined based on participant completion of daily diaries for 1-week at each assessment visit. Participants will record opioid use daily (yes/no).

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  9. Opioid morphine milligram equivalent Use

    An electronic medical chart review will determine opioid morphine milligram equivalent (MME) calculation in the past month, with higher scores indicating higher MME per day.

    Time frame: Baseline and 3 months post-intervention

  10. Patient Global Impression of Change (PGIC) Score

    The overall self-reported rating of the treatment's efficacy will be assessed with the Patient's Global Impression of Change (PGIC) instrument. The PGIC asks respondents to rate their overall improvement compared to the baseline. Responses are indicated on a scale of 1 to 7, where 1 = very much improved and 7 = very much worse. This outcome applies to teens only.

    Time frame: Baseline, 3 months and 6 months post-intervention

  11. Treatment Evaluation Inventory-Short Form (TEI-SF) Score

    Teens and parents will complete the Treatment Evaluation Inventory-Short Form at the end of treatment. This form includes 9 items adapted to be specific to pediatric pain. Items are rated on a 5-point Likert scale ranging from 1 to 5. Total scores range from 9 to 45. Higher scores indicate increased acceptability with the study treatment. This outcome applies to teens and parents

    Time frame: Immediately post-intervention

  12. Tampa Scale of Kinesiophobia (TSK) Score

    Fear of movement related to fear of pain is assessed with the Tampa Scale of Kinesiophobia (TSK) instrument. The TSK is a 17-item questionnaire where responses are given on a 4-point Likert scale. Responses of "strongly agree" are coded as 1 and responses of "strongly agree" are coded as 4. Total scores range from 17 to 68 where higher scores indicate greater kinesiophobia. This outcome applies to teens only.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  13. PROMIS Pediatric Fatigue Short Form

    Perceptions of a child's tiredness and energy will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Fatigue Short Form. It consists of 10 items scored on a Likert-type scale ranging from 1 (never) to 5 (almost always). The total possible range is 10-50, with higher scores representing greater fatigue or lower energy, while lower scores indicate better energy levels or less fatigue. The outcome applies to teens and parent-proxy.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  14. Chronic Pain Acceptance Questionnaire (CPAQ)

    The 20-item CPAQ-revised has been designed to measure acceptance of pain. The acceptance of chronic pain is thought to reduce unsuccessful attempts to avoid or control pain and thus focus on engaging in valued activities and pursuing meaningful goals. The items on the CPAQ are rated on a 7-point scale from 0 (never true) to 6 (always true). To score the CPAQ, the Activity engagement and Pain willingness items are added to obtain a score for each factor. All the scores for each factor are summed to get the total score. Higher scores indicate higher levels of acceptance. The outcome applies to teens only.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  15. Coping Self-Efficacy

    The Child Self-Efficacy Scale (CSES) is a self-report tool that examines self-efficacy despite pain to assess normal functioning and behavior. The CSES is a 7-item form asking how sure a child can perform certain activities while in pain. An 11-point scale with anchor points being 0 (cannot do at all), 5 (moderately certain can do), and 10 (certain can do). A higher score suggests that a person is more confident in their ability to cope and function with pain. The outcome applies to teens and parent-proxy.

    Time frame: Baseline, immediately post-intervention, 3 months and 6 months post-intervention

  16. Therapeutic Factor Inventory - 8 (TFI-8)

    TFI-8 is a brief, reliable, and valid measure used for continuous process measurement and feedback to improve the functioning of therapy groups. The TFI-8 is given to participants after group therapy sessions to assess group cohesion. It typically consists of 8 items that respondents rate based on their experiences. Participants usually respond using a Likert scale (e.g., 1 to 5), where 1 may indicate "strongly disagree" and 5 indicates "strongly agree." The total score is calculated by summing the responses for all items. Higher total scores generally indicate a greater presence of therapeutic factors perceived by the participants. The outcome applies to teens only.

    Time frame: Immediately post-intervention

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data will be available for sharing including study-level metadata and NIH Helping to End Addiction Long-term (HEAL) Common Data Elements.

Supporting information: Study protocol

Time frame: Data will be available for sharing beginning 9 months and ending 36 months following article publication.

Access criteria: Data for sharing will be available in an NIH HEAL-approved data repository for public use.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2027, 31 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 31 months is above that.

Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Nov 18, 2024
StartActual
Jan 8, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06691867
Lead sponsor
Emory University
Responsible party
Soumitri Sil (Associate Professor, Emory University) — Principal investigator
First posted
Nov 18, 2024
Start date
Jan 8, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Soumitri Sil, PhD, ABPP
Contact
sil@emory.edu
404-727-2712
Soumitri Sil, PhD, ABPP
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion